Combined-modality radioimmunotherapy: synergistic effect of paclitaxel and additive effect of bevacizumab-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Combined-modality radioimmunotherapy: synergistic effect of paclitaxel and additive effect of bevacizumab

Published:2012-05 Issue:4 Volume:39 Page:472-483
ISSN:0969-8051
Container-title:Nuclear Medicine and Biology
language:en
Short-container-title:Nuclear Medicine and Biology

Author:

Jang Beom-Su,Lee Sang-Myung,Kim Hyung Sub,Shin In Soo,Razjouyan Faezeh,Wang Shutao,Yao Zhengsheng,Pastan Ira,Dreher Matthew R.,Paik Chang H.

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Molecular Medicine

Reference66 articles.

1. Cell cycle alterations, apoptosis, and response to low-dose-rate radioimmunotherapy in lymphoma cells;Macklis;Int J Radiat Oncol Biol Phys,1993

2. Apoptosis-related gene and protein expression in human lymphoma xenografts (Raji) after low dose rate radiation using 67Cu-2IT-BAT-Lym-1 radioimmunotherapy;Kroger;Cancer Biother Radiopharm,2001

3. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas;Kaminski;J Clin Oncol,2001

4. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma;Witzig;J Clin Oncol,2002

5. Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma;Weigert;Cancer,2006

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modeling of chemo-radiotherapy targeting growing vascular tumors: a continuum-level approach;2024-03-27

2. Radioimmunotherapy-An Overview;Global Virology IV: Viral Disease Diagnosis and Treatment Delivery in the 21st Century;2024

3. PD-L1-Targeted Radionuclide Therapy Combined with αPD-L1 Antibody Immunotherapy Synergistically Improves the Antitumor Effect;Molecular Pharmaceutics;2022-06-02

4. Delivery of radioimmunotherapy for solid tumors;Systemic Drug Delivery Strategies;2022

5. Breaking the Silence of Tumor Response: Future Prospects of Targeted Radionuclide Therapy;Anti-Cancer Agents in Medicinal Chemistry;2021-09-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3